Mark Guttman

Best Publications

• Detection of Huntington’s disease decades before diagnosis: The Predict HD study

  Jane Paulsen;Douglas R Langbehn;Julie C Stout;Elizabeth H Aylward

  969
  Citations

• Levodopa in the treatment of Parkinson's disease: current controversies.

  C. Warren Olanow;Yves Agid;Yoshi Mizuno;Alberto Albanese

  501
  Citations

• Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

  Stephen J. Kish;Junchao Tong;Oleh Hornykiewicz;Ali Rajput

  449
  Citations

• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  Peter A. LeWitt;Peter A. LeWitt;M. Guttman;James W. Tetrud;Paul J. Tuite

  406
  Citations

• The role of radiotracer imaging in Parkinson disease

  B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  385
  Citations

• Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease

  Mark Guttman

  287
  Citations

• Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

  Mark Stacy;Annette Bowron;Mark Guttman;Robert Hauser

  282
  Citations

• Clinical markers of early disease in persons near onset of Huntington’s disease

  J. S. Paulsen;H. Zhao;J. C. Stout;R. R. Brinkman

  259
  Citations

• Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease

  J. M. Wilson;A. I. Levey;A. Rajput;L. Ang

  251
  Citations

• [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease Implications for the symptomatic threshold

  M. Guttman;J. Burkholder;S. J. Kish;D. Hussey

  233
  Citations

• Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease

  Shannon A Johnson;Shannon A Johnson;Julie C Stout;Julie C Stout;Andrea C Solomon;Douglas R Langbehn

  232
  Citations

• Thalamic metabolism and symptom onset in preclinical Huntington's disease.

  A. Feigin;C. Tang;Y. Ma;P. Mattis

  223
  Citations

• Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease

  M. Guttman;I. Boileau;J. Warsh;J. A. Saint-Cyr

  220
  Citations

• Current concepts in the diagnosis and management of Parkinson's disease

  Mark Guttman;Stephen J. Kish;Yoshiaki Furukawa

  217
  Citations

• Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation

  Junchao Tong;Henry Wong;Mark Guttman;Lee C. Ang

  213
  Citations

• Dopa decarboxylase activity of the living human brain.

  Albert Gjedde;Jakob Reith;Suzan Dyve;Gabriel Leger

  207
  Citations

• Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study

  Stephen J. Kish;Jason Lerch;Yoshiaki Furukawa;Junchao Tong

  201
  Citations

• Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD

  M. Guttman;D. Stewart;D. Hussey;A. Wilson

  199
  Citations

• Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.

  Junchao Tong;Gausiha Rathitharan;Jeffrey H Meyer;Yoshiaki Furukawa

  186
  Citations

• Burden of parkinsonism: a population-based study.

  Mark Guttman;Pamela M. Slaughter;Marc‐Erick Theriault;Donald P. DeBoer

  186
  Citations